Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hauser financials

This article was originally published in The Tan Sheet

Executive Summary

Supplement supplier "in discussions" to sell its Shuster Labs contract services division, which would generate funds to pay Wells Fargo Bank loans, "permit Hauser to obtain a new line of credit to finance operations," firm says July 1. Otherwise, Hauser may not be able to continue as a "going concern" due to "significant operating losses, existing deficit and lack of certainty as to a credit line," firm states. Company amended credit agreement with Wells on June 25 to provide for termination date of Aug. 31, 2002 instead of Aug. 31, 2003, in exchange for Wells agreeing to waive defaults under agreement. Hauser Q4 net revenue dipped 1.4% to $14.3 mil., with net loss of $1.5 mil., down from $23.1 mil. FY 2002 sales declined 13.6% to $57.6 mil., with $5.4 mil. net loss, compared to $33.3 mil. loss a year ago...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094233

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel